profile picture of Matthew Karlyn

Matthew Karlyn

Partner | Boston

Experience

USD 1.5 billion+ exclusive license agreement between CSPC Pharmaceutical Group Limited and Elevation Oncology, Inc. to supply, develop and commercialize SYSA1801, a clinical stage antibody drug conjugate (ADC) targeting Claudin18.2, in all global territories outside Greater China.

USD 700 million+ exclusive license agreement between CSPC Pharmaceutical Group Limited and Corbus Pharmaceutical Holdings to supply, develop and commercialize SYS6002, a clinical stage antibody drug conjugate (ADC) targeting Nectin-4, in the U.S., Australia, Canada, and varied European countries.



Represented ACEA Therapeutics in an exclusive license agreement with Sorrento Therapeutics to develop and commercialize Abivertinib, a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK).



Represented ACEA Therapeutics in USD 488 million merger and acquisition transaction by their licensee, Sorrento Therapeutics.



Represented Kindred Biosciences in an exclusive license agreement with Elanco Animal Health Incorporated to globally develop and commercializeKIND-030, a monoclonal antibody targeting canine parvovirus (CPV).

Represented Kindred Biosciences, Inc. in USD 440 million acquisition transaction by their licensee, Elanco US, Inc.

Represented Sanuwave Health in a license and marketing agreement with Celularity Inc. to commercialize BIOVANCE® Human Amniotic Membrane Allograft and Interfyl® Human Connective Tissue Matrix.

Represented MyChem, a privately held provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets, in connection with its ≈ USD 240 million sale to Maravai (NASDAQ: MRVI).

Represented Special New Fruit Licensing (SNFL) in its acquisition of International Fruit Genetics (IFG).



Represented Sequlite Genomics, a company that focuses on developing Next-Generation Sequencing (NGS) technology, in connection with its sale to Fapon Biotech.


Recognized among the Best Lawyers for Information Technology Law

Best Lawyers in America 2024

Band 1 in Massachusetts - Intellectual Property: Licensing

Chambers USA 2023